Objective: The use of neoadjuvant chemotherapy (NACT) in breast cancer is increasing. The management of locally advanced breast cancer differs due to the approach of the center to which the patient applied and the approach of the following physician. From this point of view, we aimed to evaluate the real life data of our region. Methods: The study included 106 patients treated with neoadjuvant chemotherapy in the medical oncology clinic of two different university hospitals. Association between clinicopathological features and pathological complete response (pCR) were analyzed. Results: The pCR rate was higher in patients with negative hormone receptors and this difference was statistically significant (p:0.000). The rate of obtaining pCR increased as the NACT duration increased, and this increase was statistically significant. The mean NACT duration applied to the patients with pCR was 5.48 ± 0.22 months, and the mean NACT duration for those who could not obtain pCR was 5.01 ± 0.1 months (p:0.041). The recurrence rate of patients with pCR was 11.1%, while the recurrence rate of patients who could not obtain pCR was 31.6% (p:0.04). Conclusions: Pathological response to chemotherapy is an important factor in determining prognosis. There appears to be a need for new biomarkers that allow the prediction of pCR and long-term outcomes.

Objectives: Pancreatic cancer (PC) is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume/ platelet (MPV/PLT) and platelet indices such as MPV and plateletcrit (PCT) have a prognostic significance in patients with metastatic PC. Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patient’s demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival (OS) and progression-free survival (PFS) were also recorded. There were 80 patients in our study. Results: Median PFS was found 6.2 months for MPV/PLT ratio 0.045 group retrospectively. The median PFS of the MPV/PLT ratio ≤0.045 groupwas shorter than MPV/PLT ratio >0.045 group, but there wasn’t statistically meaningful difference between the groups (p:0,957). Median OS for the MPV/PLT ratio ≤0.045 groupwas 10.1 months and the MPV/PLT ratio for the >0.045 group was 9 months, but there wasn’t statistically significant difference between the groups (p:0.506).There was nosurvival difference between the groups when comparing both MPV and PCT status. Conclusion: MPV/PLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

Aim: Despite many new generation treatments, it is known that the prognostic markers used to date in patients with metastatic renal cell carcinoma (mRCC), who have a very poor prognosis, can not accurately determine the prognosis in every patient. Therefore, the search for prognostic biomarkers continues. In this study, it was aimed to investigate the effect of pre-treatment biochemical parameters on oncological outcomes in mRHC patients. Material and Methods: We retrospectively evaluated the clinical, pathological, survival characteristics and factors affecting survival of 90 mRCC patients who were metastatic (stage 4) or local (stage 1-3) at the time of diagnosis in our clinic, who underwent radical nephrectomy and relapsed during follow-up. Descriptive statistical analyzes of patients' demographic, clinicopathological and treatment characteristics were performed. Results: 21.2% of the patients were female and 78.8 % were male. There was no difference in median OS (overall survival) between women and men. The median OS duration was statistically significantly lower in patients with metastasis at the time of diagnosis (p=0.001). While the median OS was 36.2 months in metastatic patients at the time of diagnosis, the median OS was 90.4 months in patients with recurrence at follow-up. As the ratio of alkaline phosphatase/Albumin (ALP/ALB) increased, survival decreased (p=0.038). While the median OS of those with a CRP/ALB ratio of 0.072 (AUC.630 p=0.046 cut off:0.072). Conclusion: It has been determined that the CRP/ALB ratio is a biomarker that determines the prognosis. We recommend immunotherapy in patients who progress after first-linetargettherapy. Today, prognosis has become important especially in the treatment decision of mRCC, and we think that our study will shedlight on the search for new prognostic markers.